Advanced search
1 file | 162.33 KB

LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life

(2018) RESPIRATION. 96(4). p.370-381
Author
Organization
Abstract
Background: While fixed dose combinations (FDCs) of long-acting beta 2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are increasingly tested on their efficacy in improving lung function, their effectiveness on Patient Reported Outcomes (PROs) such as Health Related Quality of Life (HRQoL) and Health Status (HS) deserve more attention. Objectives: To review current available evidence about the treatment effect of fixed LABA/LAMA FDCs on HRQoL. Methods: A systematic literature search for randomized controlled trials (RCTs) about the impact of LABA/LAMA FDCs versus placebo, LABA or LAMA or LABA/ICS on HRQoL in Chronic obstructive pulmonary disease (COPD) patients has been performed. Results: Twenty-eight RCTs (n = 32, 165 COPD patients) investigating the impact of fixed LABA/LAMA combinations on HRQoL were included. Using the St George' s Respiratory Questionnaire, 27 out of 28 trials assessed HRQoL. LABA/LAMA FDCs significantly improved HRQoL versus placebo in 9 out of 11 trials, while change when compared to other LABA or LAMA monocomponents was significantly better in 11 out 24. In 5 out of 6 RCTs having LABA/ICS as comparators, LABA/LAMA FDC had a similar effect and only 1 showed significant improvement in HRQL compared to LABA/ICS FDC. Conclusion: LABA/LAMA FDCs may be helpful in improving HRQoL, but because of the heterogeneity of performed trials, strong conclusions cannot be drawn. Moreover, due to the different molecule properties, treatment schedule, and device characteristics of each FDC, a generalized judgment seems inappropriate. Pragmatic trials powered to detect real-life differences in HRQoL and head-to-head comparison are needed to guide clinical practice in terms of PROs.
Keywords
Chronic obstructive pulmonary disease treatment, Long-acting beta 2-agonists/long-acting muscarinic antagonists fixed dose combinations, Randomized controlled trials, Health-related quality of life, Patient reported outcomes, ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE, UMECLIDINIUM/VILANTEROL 62.5/25 MCG, ONCE-DAILY UMECLIDINIUM/VILANTEROL, COPD ASSESSMENT TEST, PARALLEL-GROUP, DOUBLE-BLIND, FLUTICASONE PROPIONATE/SALMETEROL, SALMETEROL-FLUTICASONE, DELIVERY TECHNOLOGY, TIOTROPIUM

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 162.33 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Labor, Marina, Fulvio Braido, Andras Bikov, Lies Lahousse, Paola Rogliani, and Ilaria Baiardini. 2018. “LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life.” Respiration 96 (4): 370–381.
APA
Labor, M., Braido, F., Bikov, A., Lahousse, L., Rogliani, P., & Baiardini, I. (2018). LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. RESPIRATION, 96(4), 370–381.
Vancouver
1.
Labor M, Braido F, Bikov A, Lahousse L, Rogliani P, Baiardini I. LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life. RESPIRATION. 2018;96(4):370–81.
MLA
Labor, Marina, Fulvio Braido, Andras Bikov, et al. “LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life.” RESPIRATION 96.4 (2018): 370–381. Print.
@article{8587596,
  abstract     = {Background: While fixed dose combinations (FDCs) of long-acting beta 2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are increasingly tested on their efficacy in improving lung function, their effectiveness on Patient Reported Outcomes (PROs) such as Health Related Quality of Life (HRQoL) and Health Status (HS) deserve more attention. Objectives: To review current available evidence about the treatment effect of fixed LABA/LAMA FDCs on HRQoL. Methods: A systematic literature search for randomized controlled trials (RCTs) about the impact of LABA/LAMA FDCs versus placebo, LABA or LAMA or LABA/ICS on HRQoL in Chronic obstructive pulmonary disease (COPD) patients has been performed. Results: Twenty-eight RCTs (n = 32, 165 COPD patients) investigating the impact of fixed LABA/LAMA combinations on HRQoL were included. Using the St George' s Respiratory Questionnaire, 27 out of 28 trials assessed HRQoL. LABA/LAMA FDCs significantly improved HRQoL versus placebo in 9 out of 11 trials, while change when compared to other LABA or LAMA monocomponents was significantly better in 11 out 24. In 5 out of 6 RCTs having LABA/ICS as comparators, LABA/LAMA FDC had a similar effect and only 1 showed significant improvement in HRQL compared to LABA/ICS FDC. Conclusion: LABA/LAMA FDCs may be helpful in improving HRQoL, but because of the heterogeneity of performed trials, strong conclusions cannot be drawn. Moreover, due to the different molecule properties, treatment schedule, and device characteristics of each FDC, a generalized judgment seems inappropriate. Pragmatic trials powered to detect real-life differences in HRQoL and head-to-head comparison are needed to guide clinical practice in terms of PROs.},
  author       = {Labor, Marina and Braido, Fulvio and Bikov, Andras and Lahousse, Lies and Rogliani, Paola and Baiardini, Ilaria},
  issn         = {0025-7931},
  journal      = {RESPIRATION},
  number       = {4},
  pages        = {370--381},
  title        = {LABA/LAMA Fixed Dose Combination in Chronic Obstructive Pulmonary Disease: The Impact on Health-Related Quality of Life},
  url          = {http://dx.doi.org/10.1159/000491673},
  volume       = {96},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: